A Study of DS-3939a in Participants With Solid Tumors

A Study of DS-3939a in Participants With Solid Tumors is a phase 1/2, interventional study registered as NCT07739966 by Daiichi Sankyo, with a registry enrolment figure of 400 participants, started 2026-10-01 and due to reach its primary completion in 2030-07-31. Interventions recorded: DS-3939a; Pembrolizumab; Carboplatin; Pemetrexed; DS-1103a. Conditions listed: Solid Tumor; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer. Primary outcome: Part 1: Number of Participants With Dose-limiting Toxicities (DLTs); Part 1: Number of Participants With TEAEs; Part 2: Objective Response (OR) Per RECIST v1.1 as Assessed by Investigator. Lung eligibility wording from the registry: "Histologically documented Stage IIIB, IIIC disease who is not candidate for surgical resection or definitive chemoradiation, or Stage IV NSQ NSCLC". No results are recorded here; the registry entry is the source.